Reuters: Regulatory News: Bayer rival Boehringer seeks wider use of anti-clotting pill

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Bayer rival Boehringer seeks wider use of anti-clotting pill Jun 24th 2013, 12:14 FRANKFURT, June 24 | Mon Jun 24, 2013 8:14am EDT FRANKFURT, June 24 (Reuters) - Boehringer Ingelheim has asked European regulators to approve a wider use of its anti-blood-clotting pill Pradaxa to include the treatment of deep vein thrombosis and pulmonary embolisms. The application for approval filed with the European Medicines Agency also includes use of the drug to prevent the recurrence of the two potentially fatal conditions, the unlisted German drugmaker said in a statement on Monday. Bayer, with its rival pill Xarelto, won approval for similar uses in November. The Boehringer drug competes with Xarelto, co-developed by Bayer and Johnson & Johnson, and with Eliquis, sold by Bristol-Myers Squibb and Pfizer. The three products belong to a new class of oral anticoagulants whose largest market by far is stroke prevention in patients with a type of irregular heartbeat called atrial fibrillation.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions